查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1406708

抗体片段市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按产品类型、按应用、特异性、地区和竞争细分

Antibody Fragments Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product Type, By Application, By Specificity, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 175 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022年全球抗体片段市场价值为72.5亿美元，预计到2028年预测期内将稳定成长，复合CAGR为4.90%。在生物技术进步的推动下，全球抗体片段市场近年来出现了显着增长以及对标靶治疗的需求不断增长。抗体片段是全尺寸抗体的较小片段，在特异性、降低免疫原性和增强组织渗透性方面具有许多优势。抗体片段是透过酵素或化学裂解从单株抗体 (mAb) 衍生而来，产生保留原始抗体抗原结合特性的较小片段。这些片段包括 Fab（抗原结合片段）、F(ab')2（抗原结合片段）和单链可变片段 (scFv) 等。由于其多功能性和解决未满足的医疗需求的潜力，它们在研究和治疗应用中获得了极大的关注。

抗体片段是多种疾病标靶治疗的重要组成部分，包括癌症、自体免疫疾病和传染病。它们能够特异性结合疾病相关靶标，同时不伤害健康细胞，这使得它们在製药业中不可或缺。重组 DNA 技术和蛋白质工程的进步使得高度稳定和高效的抗体片段的开发成为可能。这扩大了它们的应用范围并改善了它们的药物动力学特性。癌症和自体免疫疾病等慢性疾病的全球增加刺激了抗体片段领域的研究和开发工作。它们为开发更有效、毒性更小的治疗方法提供了一条有前景的途径。大型製药公司正在与专门从事抗体片段技术的小型生物技术公司建立策略合作伙伴关係并签订许可协议。这些合作正在推动研究和开发计划，加速市场成长。

主要市场驱动因素

市场概况
预测期 2024-2028
2022 年市场规模 72.5亿美元
2028 年市场规模 96亿美元
2023-2028 年CAGR 4.90%
成长最快的细分市场 癌症
最大的市场 北美洲

慢性病发生率上升正在推动全球抗体片段市场

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：全球抗体片段市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品类型（FAB、scFv、sdAb、其他）
    • 按应用（癌症、免疫缺陷、其他）
    • 依特异性（单株抗体、多株抗体抗体）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图
    • 依产品类型
    • 按应用
    • 按特异性
    • 按地区

第 5 章：亚太地区抗体片段市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按应用
    • 按特异性
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国抗体片段
    • 印度抗体片段
    • 澳洲抗体片段
    • 日本抗体片段
    • 韩国抗体片段

第 6 章：欧洲抗体片段市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按应用
    • 按特异性
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 7 章：北美抗体片段市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药品类型
    • 产品类别
    • 按特异性
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 8 章：南美洲抗体片段市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按应用
    • 按特异性
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 9 章：中东和非洲抗体片段市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按应用
    • 按特异性
    • 按国家/地区
  • MEA：国家分析
    • 南非抗体片段
    • 沙乌地阿拉伯抗体片段
    • 阿联酋抗体片段
    • 埃及抗体片段

第 10 章：市场动态

  • 司机
  • 挑战

第 11 章：市场趋势与发展

  • 最近的发展
  • 产品类型发布
  • 併购

第 12 章：全球抗体片段市场：SWOT 分析

第 13 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品类型的威胁

第14章：竞争格局

  • 基因泰克公司
    • Business Overview
    • Company Snapshot
    • Product Types & Services
    • Current Capacity Analysis
    • Financials (In case of listed)
    • Recent Developments
    • SWOT Analysis
  • 艾伯维公司
  • Albynx，赛诺菲旗下公司
  • 约翰逊和约翰逊
  • 辉瑞公司
  • 百时美施贵宝
  • 礼来公司
  • 诺华公司

第 15 章：策略建议

第 16 章：关于我们与免责声明

简介目录
Product Code: 19516

Global Antibody Fragments Market has valued at USD 7.25 Billion in 2022 and is anticipated to project steady growth in the forecast period with a CAGR of 4.90% through 2028. The global antibody fragments market has witnessed remarkable growth in recent years, driven by advancements in biotechnology and a growing demand for targeted therapies. Antibody fragments are smaller fragments of full-sized antibodies, offering numerous advantages in terms of specificity, reduced immunogenicity, and enhanced tissue penetration. Antibody fragments are derived from monoclonal antibodies (mAbs) through enzymatic or chemical cleavage, resulting in smaller fragments that retain the antigen-binding properties of the original antibody. These fragments include Fab (fragment antigen-binding), F(ab')2 (fragment antigen-binding), and single-chain variable fragments (scFv), among others. They have gained significant attention in both research and therapeutic applications due to their versatility and potential to address unmet medical needs.

Antibody fragments are crucial components of targeted therapies for various diseases, including cancer, autoimmune disorders, and infectious diseases. Their ability to specifically bind to disease-associated targets while sparing healthy cells has made them indispensable in the pharmaceutical industry. Advancements in recombinant DNA technology and protein engineering have enabled the development of highly stable and efficient antibody fragments. This has expanded their range of applications and improved their pharmacokinetic properties. The global increase in chronic diseases like cancer and autoimmune disorders has spurred research and development efforts in the field of antibody fragments. They offer a promising avenue for the development of more effective and less toxic treatments. Major pharmaceutical companies are entering into strategic partnerships and licensing agreements with smaller biotechnology firms specializing in antibody fragment technologies. These collaborations are driving research and development initiatives, accelerating market growth.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 7.25 Billion
Market Size 2028USD 9.60 Billion
CAGR 2023-20284.90%
Fastest Growing SegmentCancer
Largest MarketNorth America

Rising Incidence of Chronic Diseases is Driving the Global Antibody Fragments Market

The global healthcare landscape is witnessing a significant shift as chronic diseases continue to rise at an alarming rate. Conditions such as cancer, autoimmune disorders, and cardiovascular diseases are becoming increasingly prevalent, posing a substantial burden on healthcare systems worldwide. To combat these ailments effectively, the pharmaceutical and biotechnology industries have been working tirelessly to develop innovative therapies. One such advancement that has gained substantial momentum in recent years is the use of antibody fragments. These tiny but powerful molecules are transforming the treatment landscape and are being increasingly recognized for their potential to tackle chronic diseases.

The global cancer burden continues to rise, with millions of new cases diagnosed each year. Antibody fragments are being used to target cancer cells more effectively and with fewer side effects than traditional treatments. Conditions like rheumatoid arthritis, multiple sclerosis, and lupus are on the rise, prompting the need for precise and targeted therapies. Antibody fragments are ideal for modulating the immune response in autoimmune disorders. Heart disease and related conditions remain the leading cause of death worldwide. Antibody fragments are being explored to address factors contributing to these diseases, such as inflammation and clotting. Chronic neurological diseases like Alzheimer's and Parkinson's are also increasing in prevalence. Antibody fragments are being investigated for their potential to target and clear abnormal proteins associated with these conditions.

As the need for more effective and targeted therapies for chronic diseases continues to grow, the global antibody fragments market is experiencing robust expansion. Pharmaceutical and biotechnology companies are investing heavily in research and development efforts to harness the potential of antibody fragments. This has led to a surge in clinical trials and the approval of several antibody fragment-based therapies in recent years.

Antibody fragments can be engineered for high specificity, allowing them to target disease-related molecules with remarkable precision, minimizing damage to healthy cells. Smaller size and reduced complexity make antibody fragments less likely to trigger an immune response, reducing the risk of adverse reactions. The smaller size of antibody fragments allows them to penetrate tissues and reach their target more effectively, which is particularly important in treating diseases that affect deep tissues or the brain. Antibody fragments can be developed and modified more quickly than full-sized antibodies, which is essential for responding to emerging diseases or evolving treatment needs. Antibody fragments can be used as therapeutics, diagnostics, and imaging agents, making them versatile tools in the fight against chronic diseases.

Increasing Investments in Biopharmaceuticals is Driving the Global Antibody Fragments Market

The global biopharmaceutical industry has been witnessing a remarkable surge in investments, research, and development activities in recent years. This growth is driven by the need for innovative therapeutic solutions, especially in the field of antibody-based therapies. Antibody fragments, a promising class of biopharmaceuticals, have gained significant attention due to their potential in treating a wide range of diseases. As a result, the global antibody fragments market is experiencing a robust expansion, propelled by increasing investments in biopharmaceuticals.

As precision medicine gains traction, there is a rising demand for therapies that specifically target disease-causing molecules or cells. Antibody fragments can be engineered to bind to specific targets with high precision, making them valuable tools in the development of targeted therapies. Advances in biotechnology and genetic engineering techniques have made it easier to produce and modify antibody fragments. This has significantly reduced development timelines and costs, making them an attractive investment opportunity. The versatility of antibody fragments allows them to be used in a wide range of applications, including cancer therapy, immunology, and diagnostics. This versatility increases their market potential and attracts investment from various sectors. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) have recognized the potential of antibody fragments and have streamlined approval processes for these biopharmaceuticals. This encourages investment in research and development. Several antibody fragment-based therapies have demonstrated remarkable clinical success in recent years. These success stories have instilled confidence in investors, further boosting investments in the antibody fragments market.

Key Market Challenges

Development Costs

One of the primary challenges in the antibody fragments market is the high cost of research, development, and manufacturing. Developing antibody fragments often involves intricate molecular engineering techniques and complex production processes. The need for skilled personnel, cutting-edge technologies, and high-quality facilities contributes to the overall cost. Smaller biotechnology companies, in particular, may struggle to access the necessary resources to compete effectively in this market.

Regulatory Hurdles

The regulatory pathway for antibody fragments can be arduous. Variability in the classification of antibody fragments by different regulatory agencies can lead to confusion and delays. Companies must navigate through complex regulatory frameworks to ensure that their products meet safety and efficacy standards. Achieving regulatory approval can be time-consuming and resource-intensive, discouraging some potential players from entering the market.

Intellectual Property Issues

The antibody fragments market is highly competitive, and intellectual property (IP) rights are crucial. Patents protect the novel technologies and processes used to develop antibody fragments. Fierce patent battles and disputes over IP can hinder innovation and market entry for smaller companies. Maintaining a strong and defensible IP portfolio is essential for success in this industry.

Manufacturing Scalability

Scaling up production of antibody fragments to meet market demands can be challenging. The transition from laboratory-scale to large-scale manufacturing often involves technical and logistical hurdles. Ensuring consistent product quality and cost-effective production while scaling up can be a significant barrier for companies looking to enter or expand within the market.

Competition and Market Saturation

As the antibody fragments market matures, competition among existing players intensifies. Established companies with deep pockets and extensive experience enjoy a competitive advantage. New entrants must develop innovative products or find niche applications to gain a foothold in the market. The market may also become saturated with similar products, leading to price pressures and reduced profitability.

Limited Clinical Data

Compared to full-sized antibodies, antibody fragments often have limited clinical data available. This can create challenges in convincing healthcare professionals and regulatory bodies of their safety and efficacy. Extensive clinical trials and real-world evidence are required to build confidence in these products, which can be time-consuming and costly.

Market Access and Pricing

Accessing global markets can be complicated due to differences in reimbursement policies, pricing regulations, and healthcare infrastructures. Companies must navigate various pricing and reimbursement systems, potentially affecting their product's commercial viability in different regions. Striking the right balance between affordability and profitability is a constant challenge.

Key Market Trends

Technological Advancements

Technological advancements have consistently been a catalyst for innovation and growth. The Global Antibody Fragments Market is a prime example of how these advancements are revolutionizing the field. Antibody fragments, which are smaller portions of full-sized antibodies, have emerged as versatile tools in various medical and research applications. As technology continues to advance, the global antibody fragments market is experiencing remarkable growth, with increasing demand and promising opportunities. Technological advancements have greatly improved the efficiency of producing monoclonal antibodies, which serve as the basis for creating antibody fragments. Techniques like phage display and hybridoma technology have made it easier to generate high-affinity antibody fragments.

Progress in molecular biology, including PCR (Polymerase Chain Reaction) and gene synthesis, has paved the way for the efficient manipulation of genes encoding antibody fragments. This enables the development of highly specific and customized antibody fragments for therapeutic and diagnostic purposes. Advancements in high-throughput screening techniques and bioinformatics tools have streamlined the identification and selection of potent antibody fragments. This allows researchers to target specific diseases and antigens with greater precision. Antibody fragments have found applications beyond traditional antibody therapies. They are being developed for indications such as cancer immunotherapy, autoimmune diseases, and infectious diseases. Advances in technology have made it possible to engineer antibody fragments with improved pharmacokinetics and reduced immunogenicity. Emerging biotechnology platforms, such as CRISPR-Cas9 gene editing and synthetic biology, are being harnessed to enhance the production, stability, and functionality of antibody fragments.

Segmental Insights

Type Insights

Based on the category of Type, FAB emerged as the dominant player in the global market for Antibody Fragments in 2022. The FAB region of an antibody comprises the variable domains of the heavy and light chains, which are responsible for antigen recognition and binding. FAB type antibody fragments are derived by enzymatic or chemical cleavage of full-length antibodies to isolate the FAB portion. These fragments are smaller and more manageable than full-length antibodies, making them particularly useful in diverse applications. FAB type antibody fragments maintain the high target specificity of full-length antibodies. This feature is critical for applications such as diagnostics and targeted therapies, where precise antigen recognition is essential. FAB fragments are smaller than full-length antibodies, which allows them to penetrate tissues and reach targets more efficiently. This property is advantageous for therapeutic applications, especially in the treatment of cancer and autoimmune diseases. FAB fragments have a lower risk of triggering immune responses compared to full-length antibodies. This makes them suitable for use in patients who may be more susceptible to adverse immune reactions. FAB fragments are cleared from the body more rapidly than full-length antibodies, leading to shorter half-lives. This can be advantageous when a transient effect is desired, as in certain diagnostic procedures or drug delivery applications. The production of FAB type antibody fragments is generally more cost-effective and efficient than that of full-length antibodies. This economic advantage has contributed to their dominance in the market.

Specificity Insights

The Monoclonal Antibodies segment is projected to experience rapid growth during the forecast period. Monoclonal antibodies have a well-documented history of success in both diagnostics and therapeutics. This track record has fostered trust and confidence among researchers, clinicians, and pharmaceutical companies, leading to their continued preference. Monoclonal antibodies can be designed to target a wide range of antigens, including cancer cells, pathogens, and autoimmune targets. This versatility makes them suitable for various applications, from cancer therapy to infectious disease diagnostics. Significant investments have been made in monoclonal antibody research and development, resulting in a growing pipeline of monoclonal antibody-based drugs and diagnostic tools. These ongoing innovations further solidify their dominance. Advancements in antibody engineering, such as antibody humanization and the development of bispecific antibodies, have expanded the utility of monoclonal antibodies and enhanced their therapeutic potential. Monoclonal antibodies have a well-established regulatory pathway, which has facilitated their rapid development and commercialization. This streamlined approval process contributes to their market dominance. Major pharmaceutical and biotechnology companies have invested heavily in monoclonal antibody development, creating a competitive landscape where these entities hold significant market share. Monoclonal antibodies have consistently expanded their market presence, penetrating new therapeutic areas and diagnostic applications. This expansion has allowed them to maintain their leading position.

Regional Insights

North America emerged as the dominant player in the global Antibody Fragments market in 2022, holding the largest market share in terms of value. North America boasts a robust and highly developed biotechnology ecosystem that includes top-tier pharmaceutical companies, research institutions, and biotech startups. This thriving environment encourages innovation and research, making it a hotspot for the development and production of antibody fragments. Some of the world's largest and most influential pharmaceutical companies are headquartered in North America. These industry giants have heavily invested in biologics research, including antibody fragments, leading to the development of groundbreaking therapies and diagnostic tools. North America is home to numerous research institutions and universities that are at the forefront of antibody fragment research. The collaboration between academia and industry has accelerated the discovery and development of novel antibody fragments.

Key Market Players

Genentech Inc.

AbbVie Inc.

Albynx, a Sanofi Company

Johnson and Johnson

Pfizer Inc.

Bristol-Myers Squibb

Eli Lilly and Company

Novartis AG

Report Scope:

In this report, the Global Antibody Fragments Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antibody Fragments Market, By Product Type:

  • FAB
  • scFv
  • sdAb
  • Others

Antibody Fragments Market, By Application:

  • Cancer
  • Immunodeficiency
  • Others

Antibody Fragments Market, By Specificity:

  • Monoclonal Antibodies
  • Polyclonal Antibodies

Antibody Fragments Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Antibody Fragments Market.

Available Customizations:

  • Global Antibody Fragments market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Antibody Fragments Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Product Type (FAB, scFv, sdAb, Others)
    • 4.2.2. By Application (Cancer, Immunodeficiency, Others)
    • 4.2.3. By Specificity (Monoclonal Antibodies, Polyclonal Antibodies)
    • 4.2.4. By Region
    • 4.2.5. By Company (2022)
  • 4.3. Market Map
    • 4.3.1. By Product Type
    • 4.3.2. By Application
    • 4.3.3. By Specificity
    • 4.3.4. By Region

5. Asia Pacific Antibody Fragments Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type
    • 5.2.2. By Application
    • 5.2.3. By Specificity
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Antibody Fragments Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Product Type
        • 5.3.1.2.2. By Application
        • 5.3.1.2.3. By Specificity
    • 5.3.2. India Antibody Fragments Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Product Type
        • 5.3.2.2.2. By Application
        • 5.3.2.2.3. By Specificity
    • 5.3.3. Australia Antibody Fragments Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Product Type
        • 5.3.3.2.2. By Application
        • 5.3.3.2.3. By Specificity
    • 5.3.4. Japan Antibody Fragments Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Product Type
        • 5.3.4.2.2. By Application
        • 5.3.4.2.3. By Specificity
    • 5.3.5. South Korea Antibody Fragments Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Product Type
        • 5.3.5.2.2. By Application
        • 5.3.5.2.3. By Specificity

6. Europe Antibody Fragments Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By Specificity
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Antibody Fragments Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Specificity
    • 6.3.2. Germany Antibody Fragments Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Specificity
    • 6.3.3. Spain Antibody Fragments Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Specificity
    • 6.3.4. Italy Antibody Fragments Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Product Type
        • 6.3.4.2.2. By Application
        • 6.3.4.2.3. By Specificity
    • 6.3.5. United Kingdom Antibody Fragments Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Product Type
        • 6.3.5.2.2. By Application
        • 6.3.5.2.3. By Specificity

7. North America Antibody Fragments Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Product Type
    • 7.2.2. Product Type
    • 7.2.3. By Specificity
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Antibody Fragments Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Specificity
    • 7.3.2. Mexico Antibody Fragments Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Specificity
    • 7.3.3. Canada Antibody Fragments Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Specificity

8. South America Antibody Fragments Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By Specificity
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Antibody Fragments Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Specificity
    • 8.3.2. Argentina Antibody Fragments Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Specificity
    • 8.3.3. Colombia Antibody Fragments Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Specificity

9. Middle East and Africa Antibody Fragments Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By Specificity
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Antibody Fragments Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Specificity
    • 9.3.2. Saudi Arabia Antibody Fragments Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Specificity
    • 9.3.3. UAE Antibody Fragments Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Specificity
    • 9.3.4. Egypt Antibody Fragments Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Product Type
        • 9.3.4.2.2. By Application
        • 9.3.4.2.3. By Specificity

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Type Launches
  • 11.3. Mergers & Acquisitions

12. Global Antibody Fragments Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product Type

14. Competitive Landscape

  • 14.1. Genentech Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product Types & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. AbbVie Inc.
  • 14.3. Albynx, a Sanofi Company
  • 14.4. Johnson and Johnson
  • 14.5. Pfizer Inc.
  • 14.6. Bristol-Myers Squibb
  • 14.7. Eli Lilly and Company
  • 14.8. Novartis AG

15. Strategic Recommendations

16. About Us & Disclaimer